サンプル依頼リスト カート
  • English
  • Korean
市場調査レポート
商品コード
1373388

治療用ワクチンの世界市場-2023年～2030年

Global Therapeutic Vaccines Market - 2023 -2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 186 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
治療用ワクチンの世界市場-2023年～2030年
出版日: 2023年10月18日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

治療的ワクチン接種は、感染後に抗ウイルス免疫を誘導し、それによって病気の経過を変えるために行われるものです。最終的な目的は、宿主の免疫力を変化させ、病気を根絶し、長期記憶にすることです。

ナノバイオテクノロジーの急速な進歩は、治療用がんワクチン接種の進歩を可能にしました。治療用がんワクチンの主な目的は、キラーT細胞の活性化を含む細胞性免疫反応を引き出すことです。

市場力学：市場促進要因と市場抑制要因

感染症の増加

感染症の増加は、多くの人々の生活に影響を与えています。感染症を予防するために、多くの新しい治療用ワクチンが導入されています。治療用ワクチンの技術革新の増加は、市場の成長を促進すると予想されます。

例えば、米国疾病管理センター（CDC）によると、毎年最大4億人がデング熱に感染していると推定されています。約1億人が感染症にかかり、4万人が重症のデング熱で死亡しています。

また、世界保健機関（WHO）の報告書によると、コレラ感染者は毎年130万人から400万人に上り、感染による死亡者は世界で21,000人から143,000人に上ると研究者は推定しています。コレラは、重度の脱水症状を伴う急性水様性下痢を引き起こす極めて深刻な病気です。

感染症患者数の増加は、抗原に対する免疫反応を発達させることで感染症を治療するための治療用ワクチンの需要を増加させると思われます。

阻害要因

ワクチン開発への莫大な資本支出、研究開発（R&D）コストの上昇、より複雑な疾患を対象とすることに伴う生物学的・技術的課題、より優れた医療水準との競合、安全性と有効性を証明するための臨床試験の大規模化、厳しい規制などが、予測期間中に市場が阻害されると予想される要因です。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 感染症の増加
      • YY年
    • 抑制要因
      • 製造への高額投資
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • ロシア・ウクライナ戦争の影響分析
  • DMI意見

第6章 COVID-19分析

第7章 タイプ別

  • 抗原ワクチン
  • 樹状細胞ワクチン
  • DNAワクチン
  • 腫瘍細胞ワクチン

第8章 製品別

  • 自己免疫疾患ワクチン
  • 中毒ワクチン
  • がんワクチン
  • 神経疾患ワクチン
  • 感染症ワクチン
  • その他

第9章 技術別

  • 自家ワクチン
  • 同種ワクチン

第10章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第13章 企業プロファイル

  • Elicio Therapeutics
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Argos Therapeutics
  • CSL Limited
  • Johnson & Johnson
  • AstraZeneca Plc
  • Merck & Co., Inc.,
  • Eli Lilly and Company
  • Sanofi
  • Dynavax Technologies.
  • GSK Pharmaceuticals

第14章 付録

目次
Product Code: PH1542

Overview

Therapeutic vaccination is one that is taken after infection to induce antiviral immunity and thereby change the course of the disease. It's ultimate goal is to change host immunity in order to eradicate disease and develop long-term memory.

The rapid advancement of nanobiotechnology has allowed for advancements in therapeutic cancer vaccinations. A therapeutic cancer vaccine's primary purpose is to elicit a cellular immune response, including the activation of killer T cells.

Market Dynamics: Drivers & Restraints

Increase in the prevalence of infectious diseases

The increase in infectious diseases has impacted the lives of a number of people. In order to prevent infections a number of new therapeutic vaccines have been introduced. The increase in innovations of therapeutic vaccines is expected to drive market growth.

For instance, according to the Centers for Disease Control (CDC), it is estimated that each year, up to 400 million people get infected with dengue. Approximately 100 million people get sick from infection, and 40,000 die from severe dengue.

Additionally, according to the report by World Health Organization (WHO), it is stated that researchers have estimated that every year, there are 1.3 to 4.0 million cases of cholera, and 21 000 to 143 000 deaths worldwide due to the infection. Cholera is considered an extremely serious disease that can cause severe acute watery diarrhea with severe dehydration.

The increase in the number of infectious diseases will increase the demand for therapeutic vaccines in order to treat infectious diseases by developing an immune response against the antigens present.

Restraint

Huge capital expenditure on vaccine development, the rising cost of research and development (R&D), biological and technical challenges associated with targeting more complex diseases, competition with better standards of care, the larger scale of clinical studies to prove safety and efficacy, and stringent regulations are the factors the market is expected to get hampered in the forecast period.

Segment Analysis

The global therapeutic vaccines market is segmented based on type, products, technology, distribution channel and region.

Cancer vaccines segment accounted for 38.3% of the market share

The ability to deliver all potential antigens to the immune system is the most essential advantage of cancer vaccines. Cancer vaccines, either allogeneic or autologous, can be created and delivered to patients using irradiation of whole cells or cell lysates.

Cancer vaccines segment has been holding a dominant segment in the therapeutic vaccines market due to the rise in the number of different cancers that can be treated through therapeutic vaccines. It is expected to continue throughout the forecast period. For instance, according to the American Society of Cancer, it is estimated that about 288,930 new cancer cases are to be diagnosed.

Additionally, it is estimated that about 82,290 new bladder cancer cases and 97,610 melanoma cases are to be diagnosed in the year 2023. The availability of tumor cell vaccines is expected to treat cancers. Thus, an increase in the incidence of cancer cases is expected to raise the growth of the segment.

Geographical Analysis

North America is expected to hold a significant position in the global therapeutic vaccines market share

North America is a dominant force in the global therapeutic vaccine market. The rising incidence of chronic infectious diseases, cancer, and Alzheimer's, are the factors that are driving the market growth. It is expected to continue throughout the forecast period.

According to Alzheimer's San Diego Organization, it is estimated that at least one person in America develops Alzheimer's every 67 seconds. It is estimated that nearly 500,000 new cases of Alzheimer's disease will be diagnosed in 2023.

Additionally, according to the American Society of Cancer, it is estimated that about 81,800 new cases of kidney cancer will be diagnosed. Thus, an increase in disease conditions is expected to increase the demand for therapeutic vaccines.

Also, the presence of key manufacturers, increasing investments by pharmaceutical companies for vaccine development in the region, proactive government initiatives, favorable subsidiaries, and a large patient pool are driving the market in North America.

COVID-19 Impact Analysis:

COVID-19 has impacted the growth of the market positively. There is a rise in the demand for therapeutic vaccines during this period. The increase in the cases of COVID-19 has increased the emergency and demand for the production of therapeutic vaccines which have the ability to produce antibodies against the virus.

Competitive Landscape

The leading companies with a significant market share in global therapeutic vaccines include: Elicio Therapeutics, Argos Therapeutics, CSL Limited, Johnson & Johnson, AstraZeneca Plc, Merck & Co., Inc., Eli Lilly and Company, Sanofi, Dynavax Technologies., and GSK Pharmaceuticals among others.

Key Developments

  • On January 24, 2023, the Serum Institute of India (SII) launched India's First Indigenously Made Cervical Cancer Vaccine 'CERVAVAC'.
  • On May 11, 2023, TechInvention Lifecare India in partnership with Eubiologics Co, South Korea, launched Euvichol-Plus, an oral cholera vaccine in India.

Why Purchase the Report?

  • To visualize the global therapeutic vaccines market segmentation based on type, products, technology, distribution channel and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of therapeutic vaccines market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global therapeutic vaccines market report would provide approximately 69 tables, 70 figures, and 183 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Products
  • 3.3. Snippet by Technology
  • 3.4. Snippet by Distribution Channel
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increase in the prevalence of infectious diseases
      • 4.1.1.2.
    • 4.1.2. Restraints
      • 4.1.2.1. High investments in manufacturing
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine War Impact Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Antigen Vaccines *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Dendritic Cell Vaccine
  • 7.4. DNA Vaccine
  • 7.5. Tumor Cell Vaccines

8. By Products

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products
    • 8.1.2. Market Attractiveness Index, By Products
  • 8.2. Autoimmune Disease Vaccine *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Addiction Vaccine
  • 8.4. Cancer Vaccines
  • 8.5. Neurological Disease Vaccine
  • 8.6. Infectious Disease Vaccine
  • 8.7. Others

9. By Technology

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.1.2. Market Attractiveness Index, By Technology
  • 9.2. Autologous Vaccines *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Allogeneic Vaccines

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.1.2. Market Attractiveness Index, By Distribution Channel
  • 10.2. Hospital Pharmacies *
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Retail Pharmacies
  • 10.4. Online Pharmacies

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. UK
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Elicio Therapeutics *
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Argos Therapeutics
  • 13.3. CSL Limited
  • 13.4. Johnson & Johnson
  • 13.5. AstraZeneca Plc
  • 13.6. Merck & Co., Inc.,
  • 13.7. Eli Lilly and Company
  • 13.8. Sanofi
  • 13.9. Dynavax Technologies.
  • 13.10. GSK Pharmaceuticals

LIST NOT EXHAUSTIVE.

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us